Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward ... .
) FORM 4 ... See Instruction 1(b) ... OMBNumber ... 0.5 ... ELI LILLY & Co [LLY] 5 ... LILLY CORPORATE CENTER 3 ... LILLY CORPORATE CENTER ... Eli Lilly and Company published this content on November 17, 2026, and is solely responsible for the information contained herein.
Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity ... .
Nov 16 (Reuters) - Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers ....
Nov 16 (Reuters) - Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday ....
pharmaceutical company Eli Lilly’s next-generation obesity treatment candidate in animal testing, along with a lower rate of weight regain after discontinuation.
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes ....